Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

Core Viewpoint - Ascendis Pharma A/S has announced a share repurchase program and net settlement of restricted stock units (RSUs) to preserve approximately 200,000 American Depositary Shares (ADSs) held as treasury shares, with a total expected expenditure of around $25 million [1][3]. Share Repurchase Program - The Board of Directors has authorized the repurchase of up to$18.25 million of the Company's ADSs, which represent ordinary shares of Ascendis Pharma A/S [2][4]. - The repurchases will be conducted in compliance with U.S. securities regulations and may utilize various methods including open market purchases and block trades [4]. Net Settlement of RSUs - The Company plans to net settle tax-withholding obligations related to the vesting of approximately 450,000 RSUs, amounting to about $9 million, which will help preserve around 75,000 ADSs as treasury shares [3]. Overall Strategy - The combined efforts of the Share Repurchase Program and the Net Settlement of RSUs are aimed at maintaining a total of approximately 200,000 ADSs in treasury [1][3]. Company Overview - Ascendis Pharma is focused on utilizing its TransCon technology platform to develop innovative therapies, with a commitment to improving patients' lives [5].